High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome
Open Access
- 5 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Advances in Rheumatology
- Vol. 61 (1), 1-10
- https://doi.org/10.1186/s42358-021-00199-z
Abstract
Background: The protein chitinase-3-like-1 (YKL-40) is rarely analyzed in patients with myositis. Therefore, we aimed to evaluate YKL-40 serum levels; correlate them with laboratory and clinical parameters, disease status, and treatment schemes; and analyze the YKL-40 expression in the muscle tissues of patients with antisynthetase syndrome (ASSD). Methods: This cross-sectional single-center study included 64 adult patients with ASSD who were age-, gender-, and ethnicity-matched to 64 healthy control individuals. Their YKL-40 serum levels were analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA) kit method, while YKL-40 expression in muscle tissues was analyzed using an immunohistochemical technique. Disease status was assessed using the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. Results: The patients’ mean age was 44.8 ± 11.8 years, and median disease duration was 1.5 (0.0–4.0) years. These patients were predominantly female (82.8%) and Caucasian (73.4%). Most patients had stable disease. The median YKL-40 serum level was significantly higher in patients with ASSD when compared to the healthy individuals: 538.4 (363.4–853.1) pg/mL versus 270.0 (201.8–451.9) pg/mL, respectively; P < 0.001. However, YKL-40 serum levels did not correlate with any clinical, laboratory, disease status, or therapeutic parameters (P > 0.050), except tumor necrosis factor alpha (TNF-α) serum levels (Spearman’s correlation, rho = 0.382; P = 0.007). YKL-40 was highly expressed by inflammatory cells found in muscle biopsy specimens. Conclusions: High YKL-40 serum levels were observed in patients with ASSD and correlated positively with TNF-α serum levels. Moreover, YKL-40 was expressed by the inflammatory cells of the muscle tissue.Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/09079-1)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (303379/2018-9)
- Faculdade de Medicina da USP - SP (.)
This publication has 35 references indexed in Scilit:
- Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositisClinics, 2013
- Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and InjuryAnnual Review of Physiology, 2011
- YKL-40: A Potential Biomarker for OsteoarthritisJournal of International Medical Research, 2009
- Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositisRheumatology, 2008
- Cytokines in idiopathic inflammatory myopathiesAutoimmunity, 2006
- High serum levels of YKL‐40 in patients with systemic sclerosis are associated with pulmonary involvementScandinavian Journal of Rheumatology, 2005
- Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathiesRheumatology, 2001
- YKL-40 (Cartilage gp-39) Induces Proliferative Events in Cultured Chondrocytes and Synoviocytes and Increases Glycosaminoglycan Synthesis in ChondrocytesBiochemical and Biophysical Research Communications, 2001
- Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessmentsArthritis & Rheumatism, 1997
- Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controlsJournal of Neuroimmunology, 1995